Roche still quiet on Avastin breast cancer failure
This article was originally published in Scrip
Executive Summary
Roche's hopes for Avastin (bevacizumab) in earlier breast cancer as an adjuvant therapy look somewhat diminished given the failure of the Phase III BEATRICE trial in triple negative patients to meet its primary endpoint. The result is a setback for Roche's Avastin expansion strategy which has seen the company run a series of clinical studies designed to show that early and uninterrupted use of the drug offers the greatest efficacy for patients (scripintelligence.com, 5 June 2012).